ReviewCancers2021
Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials.BMJ open · 2024Pooled it
- Digital solutions for tackling mental health in cancer patients and their families: The ALTHEA project.PLOS digital health · 2026Article
- Pilot study on RECAF (Receptor for Alpha-Fetoprotein) expression in pediatric acute leukemia: insights from flow cytometry analysis.Journal of the Egyptian National Cancer Institute · 2026Article
- Repair of DNA double-strand breaks after low radiation doses in childhood cancer survivors and matched cancer-free individuals.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Long-Acting Therapeutics in Pediatric Health: Bridging Innovation and Access.Clinical pharmacology and therapeutics · 2026Review
- Copy number variation analysis of cerebrospinal fluid metagenomic next-generation sequencing data in assisting the diagnosis of pediatric brain tumors.Pediatric investigation · 2026Article
- Prevalence of respiratory complications in long-term survivors of childhood and adolescent cancer: a systematic review and meta-analysis.Translational pediatrics · 2026Article
- Language Processing in Posterior Fossa Tumour Patients: Psycholinguistic Insights into the Word-Finding Ability.Cerebellum (London, England) · 2026Article
- Optimizing the Efficacy-Toxicity Paradigm in Pediatric Oncology: A Narrative Review of Immunotherapy and Survivorship Outcomes.Current oncology (Toronto, Ont.) · 2026Review
- Incidence of Second Malignancies Among Children Treated for Cancer With Radiotherapy in Egypt.Cancer reports (Hoboken, N.J.) · 2026Article
- Elimusertib enhances cytotoxic effects of conventional chemotherapy and sensitizes to radiation in preclinical Ewing sarcoma models.Scientific reports · 2026Article
- Benefits of Physiotherapy Interventions in Survivors of Childhood Cancer: A Systematic Review with Meta-Analysis.Cancers · 2026Review
- Integrative Genomic Profiling of Pediatric Solid Tumors Reveals Clinically Relevant Variants and Chromosomal Arm Aneuploidies Signatures.Cancer medicine · 2026Article
- Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
- The risk of developing acute myeloid leukemia in patients with Ewing sarcoma and trend analysis: a SEER-based study.Annals of medicine and surgery (2012) · 2026Article
- Circulating Tumor DNA and microRNA-Based Liquid Biopsy for Longitudinal Treatment Monitoring and Recurrence Prediction in Pediatric Sarcomas: A Prospective Cohort Study.Oncology research · 2026Article
- The role of mesenchymal stem cells and quercetin in preserving fertility in prepubertal male mice exposed to cyclophosphamide.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Precision Pediatric Cancer Nanomedicine: Advancing Personalized Nano Therapies to Reduce Non-Communicable Diseases Through AI-Driven 3D-Printed Drugs.International journal of nanomedicine · 2026Review
- Self-Concept in Pediatric Cancer Patients.Advances in experimental medicine and biology · 2026Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cancer represents the leading cause of disease-related death and treatment-associated morbidity in children with an increasing trend in recent decades worldwide. Nevertheless, the 5-year survival of childhood cancer patients has been raised impressively to more than 80% during the past decades, primarily attributed to improved diagnostic technologies and multiagent cytotoxic regimens. This strong benefit of more efficient tumor control and prolonged survival is compromised by an increased risk of adverse and fatal late sequelae. Long-term survivors of pediatric tumors are at the utmost risk for non-carcinogenic late effects such as cardiomyopathies, neurotoxicity, or pneumopathies, as well as the development of secondary primary malignancies as the most detrimental consequence of genotoxic chemo- and radiotherapy. Promising approaches to reducing the risk of adverse late effects in childhood cancer survivors include high precision irradiation techniques like proton radiotherapy or non-genotoxic targeted therapies and immune-based treatments. However, to date, these therapies are rarely used to treat pediatric cancer patients and survival rates, as well as incidences of late effects, have changed little over the past two decades in this population. Here we provide an overview of the epidemiology and etiology of childhood cancers, current developments for their treatment, and therapy-related adverse late health consequences with a special focus on second primary malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.